Abiopharma

🔍 Kelly James Patrick (Executive)

Company: NOVAVAX INC (NVAX)

Report Date: 2026-03-07

Detailed Transactions and Holdings:

• Acquired 12,223 shares of Common Stock (Direct)
  Date: 2026-03-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 136,503.00 | transaction_form_type: 4
• Sold 5,904 shares of Common Stock at $9.98 per share (Direct)
  Date: 2026-03-07 | Code: F | equity_swap_involved: 0 | shares_owned_after: 130,599.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 12,223 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-07 | Code: M | Expires: 2033-03-07 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
• F2: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date.